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Abstract Gene expression profiles provide important infor-
mation about the biology of breast tumors and can be used
to develop prognostic tests. However, the implementation of
quantitative RNA-based testing in routine molecular pathol-
ogy has not been accomplished, so far. The EndoPredict
assay has recently been described as a quantitative RT-PCR-
based multigene expression test to identify a subgroup of
hormone–receptor-positive tumors that have an excellent
prognosis with endocrine therapy only. To transfer this test
from bench to bedside, it is essential to evaluate the test–
performance in a multicenter setting in different molecular
pathology laboratories. In this study, we have evaluated the
EndoPredict (EP) assay in seven different molecular pathol-
ogy laboratories in Germany, Austria, and Switzerland. A
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DOI 10.1007/s00428-012-1204-4set of ten formalin-fixed paraffin-embedded tumors was
tested in the different labs, and the variance and accuracy
of the EndoPredict assays were determined using predefined
reference values. Extraction of a sufficient amount of RNA
and generation of a valid EP score was possible for all 70
study samples (100%). The EP scores measured by the
individual participants showed an excellent correlation with
the reference values, respectively, as reflected by Pearson
correlation coefficients ranging from 0.987 to 0.999. The
Pearson correlation coefficient of all values compared to the
reference value was 0.994. All laboratories determined EP
scores for all samples differing not more than 1.0 score units
from the pre-defined references. All samples were assigned
to the correct EP risk group, resulting in a sensitivity and
specificity of 100%, a concordance of 100%, and a kappa of
1.0. Taken together, the EndoPredict test could be success-
fully implemented in all seven participating laboratories and
is feasible for reliable decentralized assessment of gene
expression in luminal breast cancer.
Keywords Breastcancer.Prognosis.mRNA.Quality
control
Introduction
The success of individualized cancer therapy critically
depends on reliable molecular biomarker assays that identify
those tumors that have a particular good response to a
defined treatment.
In the last years, molecular assays for prediction of ther-
apy response have been established in colon cancer and non-
small cell lung cancer. These assays are based on retrospec-
tive evaluation of clinical trials that had been performed to
evaluate new therapeutic approaches [1, 2]. It has been
shown that determination of EGFR and KRAS mutations in
formalin-fixed paraffin-embedded (FFPE) tissues can be
performed reliably in the routine molecular pathology labo-
ratory [3, 4].
While this approach is now routine for colorectal and
lung cancer, the molecular characterization of breast cancer
in the pathology institutes is largely based on immunohis-
tochemical evaluation of hormone receptors and HER2 [5,
6]. However, one central clinical question in breast cancer is
the identification of those tumors that have an excellent
outcome with endocrine therapy alone—a task which cannot
be accomplished by standard immunohistochemistry.
It has been shown in several studies that gene expression
analysis can identify subgroups of breast tumors with good
outcome under endocrine therapy [7–10]. Based on these
observations, molecular assays have been developed that are
currently performed centralized in reference laboratories in
Europe [11] and the USA [12, 13]. These assays provide
useful information for treatment strategies; however, they
are not linked to the histopathology workflow in the local
pathology laboratory. As most of the tissue-derived infor-
mation is generated in clinical pathology laboratories, it
would improve the acceptance of the new technologies if
the molecular assay would be available in each pathology
institute that diagnoses the breast cancer cases anyway.
We have recently described a quantitative reverse tran-
scription polymerase chain reaction (RT-qPCR)-based mo-
lecular assay that uses routine FFPE tissue samples and
identifies a subgroup of breast cancer cases that have an
excellent prognosis if treated with endocrine therapy alone,
without additional chemotherapy [14]. The assay measures
the expression of eight functional genes and three normali-
zation genes as well as the presence of genomic DNA to
calculate the EndoPredict score (EP score) ranging from 0 to
15. Using the validated cutoff value of 5, patients can be
classified into low or high risk for the occurrence of distant
recurrence under endocrine therapy. The molecular score
can subsequently be combined with the nodal status and
the tumor size to calculate the integrated molecular and
clinical risk score (EPclin). The EPclin score is superior
over the EP score as the outcome of breast cancer cannot
be predicted optimally by gene expression data alone [14].
Clinical parameters reflecting the size and the dissemination
status of the tumor are not necessarily reflected by tumor
RNA expression.
The EndoPredict score had been generated in a cohort of
964 ER-positive, HER2-negative tumors. After transfer to
the RT-qPCR platform, the test was validated independently
in two separate clinical cohorts, the ABCSG-6 (n0378), and
the ABCSG-8 (n01,324) cohort [14]. This validation ap-
proach resulted in a level of evidence of 1 according to the
classification scheme for biomarker studies that has been
suggested by Simon et al. [15].
The next and essential step would be to transfer this
molecular testing system to the individual clinical pathology
laboratories. In this study, we report the results of the pro-
ficiency testing program, which show that the EndoPredict
test can be executed reliably and de-centralized in molecu-
lar–pathological laboratories. Aim of the study was to eval-
uate the performance of the test in the different molecular
pathology laboratories and to determine the number of lab-
oratories that have implemented the EndoPredict test
successfully.
Methods
Materials and study logistics Ten-micrometer sections of
ten FFPE breast cancer tumor blocks were shipped to the
seven participating laboratories: Institute of Pathology,
Charité Hospital, Berlin; Institute of Pathology, Gelsenkirchen,
252 Virchows Arch (2012) 460:251–259Germany; Institute of Pathology, Medizinische Hochschule
Hannover, Germany; Institute of Pathology, University of Hei-
delberg, Germany; Institute of Pathology and Pathological
Anatomy, Technical University of Munich, Germany; Institute
of Pathology, Medizinische Universität Wien, Vienna, Austria;
and Institute of Surgical Pathology, University Hospital Zurich,
Switzerland. Selection criteria for these institutions were (1)
experience in high-volume diagnostic molecular pathology and
breast pathology, (2) localization in different countries
(Germany, Austria, or Switzerland); (3) different organi-
zational structure (university hospital or large specialized
private institution). The pathological data of the tumors
are shown in Table 1, the steps for development of the
EndoPredict assay and the workflow of the study are
incorporated in Fig. 1.
Adjacent sections were used for histopathological quality
control to ensure that the sample used for the molecular
analysis contains at least 30% of tumor tissue. The range
of tumor content of the samples was 30–80%, mean tumor
content 63%.
For each block, a reference EP score was generated in
Sividon’s laboratory by measurement of four further sec-
tions of each tumor. The reference values were calculated as
means of these four replicate measurements. The range of
the EP scores of the ten tumors was from 2.7 to 12.1. For
this analytical evaluation of the EndoPredict assay, the sam-
ples were chosen to cover the range of possible EP scores.
These reference EP scores were not provided to the study
participants until the study was completed and were only
used for the final analysis. A random unique number iden-
tified each section; the association between an individual
section, and the block of origin was unknown to the study
participants.
Pre-specified analysis plan Study aims and statistical anal-
ysis plan were defined prospectively. The primary aim of the
study was to determine the number of pathology laboratories
that have implemented the EndoPredict assay successfully.
For a successful implementation, it was required that the
absolute difference between the local EP score and the refer-
ence EP score was below 1.0 EP units for at least nine of ten
samples.ThepredefinedsecondaryaimsareshowninTable2.
In the event that the analysis could not be completed due to
technical reasons or out-of-specification controls the labora-
tory could ask for replacement sections. The total number of
replacement sections and the number of repeated plates were
recorded.
RNA isolation from FFPE tissue Total RNA was extracted
from one FFPE tissue section of each of the ten FFPE tumor
blocks, respectively, using a silica-coated magnetic bead-
based method developed by Siemens Healthcare Diagnos-
tics (Marburg, Germany) as published previously [16–19].
The method was either performed manually or automatically,
depending on the robotic equipment available at each site.
DNA-free total RNA from one FFPE section was finally
eluted with 100 μl of elution buffer. For the assessment of
DNA contamination in the respective RNA extract, an HBB-
DNA-specific qPCR was included in the EndoPredict assay.
Samples were considered to be substantially free of DNA
when Ct values above 38 were detected. In case of DNA
contamination, samples were manually re-digested by DNase
I treatment.
Gene expression analysis using RT-qPCR Expression of
eight genes-of-interest (AZGP1, BIRC5, DHCR7, IL6ST,
MGP, RBBP8, STC2, UBE2C), three normalization genes
(CALM2, OAZ1, RPL37A) as well as the amount of residual
genomic DNA (HBB) were assessed by the EndoPredict®
assay (Sividon Diagnostics, Cologne, Germany). This assay
is configured on a 96-well plate containing primers and
FAM/TAMRA-labeled probes dried into the wells. Each
EndoPredict plate contains PCR assays for two tumor sam-
ples as well as one positive and one negative control for
each gene. Genes were measured in triplicates as a necessary
means to control for PCR imprecision and to enable outlier
Table 1 Clinicopathological
parameters Sample ID Tumor content (%) Grade pT stage pN stage ER (%) PR (%)
A 60 2 pT2 pN0 100 60
B 75 2 pT2 pN0(sn) 90 10
C 65 3 pT2(m) pN2a 95 40
D 80 1 pT2 pN0 Pos. n.d.
E 65 2 pT1c pN0 100 0
F 75 2 pT2 pN0(sn) Pos. n.d.
G 30 1 pT2 pN1mi 100 30
H 70 3 pT2 pN2a 90 80
I 60 2 pT2 pN3a 90 8
J 75 2 pT3(m) pN1a 95 0
Virchows Arch (2012) 460:251–259 253removal. Sequences of primers and probes were published
previously [14]. Gene expression was assessed by one-step
RT-qPCR using the SuperScript III PLATINUM One-Step
Quantitative RT-PCR System with ROX (Invitrogen,
Multicenter training cohort (n=964)  
Inclusion criteria: ER+/HER2-; Node +/-
Tam Monotherapy 
Platform: Affymetrix Microarray, RT-qPCR 
ABCSG6 validation cohort (n=378)  
Inclusion criteria: ER+/HER2-; Node +/- 
Tam vs. 1st gen AI
Platform: RT-qPCR
ABCSG8 validation cohort (n=1324)  
Inclusion criteria: ER+/HER2-; Node +/- 
Tam/anastrozol
Platform: RT-qPCR
(Filipits et al, 201114)
Transfer to RT-qPCR 
Definition of EndoPredict algorithm 
Definition of cutoff 
Method development for RNA extraction 
from FFPE tissue 
(Bohmann et al. 200916, Müller et al. 201118)
Platform: RT-qPCR
Central analytical validation of operational  
performance at Sividon Diagnostics
Platform: RT-qPCR
Decentral analytical validation of
operational performance at Charité 
Platform: RT-qPCR
NEOpredict project 
Transfer of RNA extraction and qRT-PCR  
system to routine diagnostic platform
Denkert et al. 201019
CLINICAL VALIDATION ANALYTICAL VALIDATION
TRAINING
Clinical 
validation
1
Clinical 
validation
2
Method
develop-
ment / 
transfer
Method
validation
1
Method
validation
2
Prospective analytical validation in seven 
molecular pathology laboratories
Berlin, Gelsenkirchen, Hannover, Heidelberg, Munich  , 
Vienna, Zürich 
Prespecified analysis plan
Distribution of test sections for analysis of EndoPredict test  
Analysis of results 
Fig. 1 Workflow of sequential validation of the EndoPredict assay and the interlaboratory quality assurance (ER estrogen receptor)
Table 2 Predefined study aims and summary of the results
Primary aim Results
Determine the number of participating laboratories that successfully implement
the EndoPredict test. A successful implementation is achieved if the absolute
difference between EP scores determined in the laboratory and the corresponding
reference EP scores is below 1.0 EP score units for at least 9 of the 10 samples.
100% (7 of 7)
Secondary aims
1. Determine the number and ratio of sections for which the EP score was
successfully measured (across all blocks and laboratories).
98.6% (69 of 70)
2. Determine the (mean) standard deviation of EP scores between laboratories
(including one result per block from Sividon). Results per block are summarized
by averaging the corresponding variances.
0.25 score units (1.7% of EP score range)
3. Determine the number and ratio of EP scores deviating more than 2.0 EP score
units from the reference EP score across all blocks and laboratories (outliers).
The same analysis will be done for deviations of more than 1.0 and 0.5 EP score units.
Deviation of more than 2.0 units:
0 of 70 samples
Deviation of more than 1.0 units:
0 of 70 samples (one sample had a
deviation of exact 1.0 score unit)
Deviation of more than 0.5 units:
10 of 70 samples (14%)
4. Calculate the Pearson correlation coefficient between the reference EP scores and the EP
scores reported by the participating laboratories (across all blocks and laboratories).
0.994
5. Calculate the EP classes from the EP scores. Determine the number and ratio of EP
classes discordant to the corresponding reference EP classes across all blocks for
each laboratory (across all laboratories). Also, report contingency table, kappa
statistics, sensitivity, and specificity.
All EP classes were calculated correctly,
resulting in a sensitivity and specificity
of 100% and a kappa of 1.0.
254 Virchows Arch (2012) 460:251–259Karlsruhe, Germany) according to manufacturer’s instruc-
tions in a VERSANT® kPCR Molecular System (Siemens
Healthcare Diagnostics) with 30 min at 50°C, 2 min at 95°C
followed by 40 cycles of 15 s at 95°C and 30 s at 60°C.
Mastermix containing 1 μl sample RNA for each well was
added to the respective wells. As positive controls of RT-
qPCR assays a standardized reference RNA (Stratagene
qPCR Human Reference Total RNA, Agilent Technologies,
Waldbronn, Germany) was tested for each gene on each
plate. As positive control for HBB–DNA PCR assay Human
Genomic DNA (Roche Applied Bioscience, Mannheim,
Germany) was used. For exclusion of contamination no-
template-controls were assessed in parallel as well. Detec-
tion of outliers which were defined by a difference of more
than three “noise model”-predicted standard deviations from
the other replicates, relative expression levels of each gene
of interest as well as EP scores were calculated as described
previously [14] using a web-based implementation to pro-
cess analytical PCR results into EP scores which can be
found at http://forschung.medizin.uni-mainz.de/epreport/.
The amount of input RNAwas assessed by the EndoPredict
assay using the mean of the Ct values of the three normal-
ization genes as surrogate. RNA input was considered as
sufficient if the mean of the ct values of CALM2, OAZ1 and
RPL37A of a tumor sample was below 28. Before the start of
the proficiency testing program, each participant performed
a pre-defined analytical validation of the performance char-
acteristics of the EndoPredict assay.
Evaluation of study results After completion of the PCR, for
each sample, analytical data (raw data of PCR run), calculated
EP score as well as classification into low or high risk of
distant metastasis were reported to Sividon and to Charité,
who performed the data analysis according to the pre-defined
analysis plan. After completion of the study, summary results
and reference EP scores were disclosed to all participants.
Results
Successful implementation of the EndoPredict assay—
primary study aim The EndoPredict test could be success-
fully implemented in all seven participating laboratories. As
defined in the study plan, a successful implementation was
achieved, if the absolute difference between EP scores de-
termined in the participating laboratoryand the corresponding
reference EP scores was below 1.0 EP score units for at least
nine of the ten samples. Six of the seven laboratories have
reached a difference below 1.0 score units for all ten samples.
One laboratory had differences below 1.0 score units for nine
of ten samples and a difference of exactly 1.0 score unit for a
single sample.
Therefore, the EP scores of 69 of the 70 measurements were
correct with respect to the reference value and one was just at
the pre-specified cutoff. For the EP score, the results of the
individual measurements are shown in Fig. 2. As shown in
Fig. 3, there was a high concordance in the analysis of the
differentgenes in the seven laboratories.The EndoPredict score
is arranged as a linear combination of eight genes for increased
robustness. Three genes (BIRC5, DHCR7, UBE2C)a r ep o s i -
tively associated with the EP score, the other genes (AZGP1,
IL6ST, MGP, RBBP8, STC2) yield to a smaller score the higher
they are expressed. For details on the biological interpretation
of the genes, see supplementary appendix in Filipits et al. [14].
Variation, correlation and concordance of results—second-
ary study aims The results of the analysis of the secondary
study aims are shown in Table 2. Extraction of a sufficient
amount of RNA and generation of a valid EP score was
possible for all 70 study samples (100%); it was not required
to ship any extra tissue sections for additional measure-
ments. For four of the 70 samples (two EndoPredict plates),
the RT-qPCR analysis had to be repeated. This was due to an
instrument problem and one positive control that was out of
the prespecified range. Averaging the corresponding varian-
ces per tumor block, the mean standard deviation of all 80
measurements (70 decentral measurements and ten central
reference values) in ten tumor blocks was 0.25 score units.
Eighty-six percent of the samples had a difference between
local analysis and central reference value of 0.5 score units
or less. The EP scores measured by the individual partic-
ipants showed an excellent correlation with the reference
values, respectively, as reflected by Pearson correlation
coefficientsranging from0.987 to0.999 (Fig. 4).The Pearson
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Fig. 2 Results of the decentral measurement of 70 tumor samples from
ten different tumors. The central reference value is marked in red, the
blue labels represent the seven different measurements at the seven
institutes of pathology
Virchows Arch (2012) 460:251–259 255correlation coefficient of all values compared to the reference
value was 0.994. All samples were assigned to the correct EP
risk group, resulting in a sensitivity and specificity of 100%, a
concordance of 100%, and a kappa of 1.0.
Discussion
In this study, we have tested the EndoPredict assay in seven
different molecular pathology laboratories in Germany, Aus-
tria, and Switzerland. All laboratories fulfilled the pre-
specified quality criteria and are thus qualified to run the
test. For 69 of 70 samples, the quantitative EP score was
measured correctly with an EP score deviation of less than
1.0 score units. Only one sample had a deviation of exactly
1.0 score unit and missed the pre-specified threshold mar-
ginally. Nevertheless, all 70 samples were assigned to the
correct EP risk group (low risk or high risk).
The data demonstrate that the EndoPredict assay is a
reproducible and easy-to-perform prognostic multigene
expression test, which can easily be included in the routine
workflow of patient care in breast cancer centers. The
decentral use of the EndoPredict assay, a unique feature
which has not been shown for other RNA-based multigene
expression tests so far, has several advantages in comparison
to centralized diagnostic services. The analysis can be inte-
grated into the regular diagnostic workflow and the clinic–
diagnostic setup in the setting of established local tumor
boards with a clear interdisciplinary communication strategy.
Moreover, the local pathologist can select optimal FFPE tu-
mor material for this complex multigene assay ensuring high-
quality on-site testing. Since no shipping of tumor material is
necessary and the EndoPredict assay can be performed within
one working day, results are promptly available for clinical
decisionmaking.Therefore,the EndoPredictassayisdifferent
from the Recurrence Score [20], which is based on an assess-
mentinacentrallaboratoryaswellastheUPA/PAIassay[21],
which requires fresh-frozen tissue.
It should be noted, however, that despite the excellent
results of this proficiency testing, the standardized evalua-
tion of quantitative RNA markers is not an easy and
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Participant 1
Participant 2
Participant 3
Participant 4
Participant 5
Participant 6
Participant 7
 
B
I
R
C
5
 
D
H
C
R
7
 
U
B
E
2
C
 
A
Z
G
P
1
 
I
L
6
S
T
 
M
G
P
 
R
B
B
P
8
 
S
T
C
2
 
E
P
E
G
J
D
A
H
B
F
C
I
t
u
m
o
r
 
n
o
.
gene expression
Fig. 3 Cluster analysis of the results of the RT-qPCR in the different centers. The EndoPredict score is shown on the right
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Virchows Arch (2012) 460:251–259 257straightforward task. The essential elements are highly stan-
dardized reagents and controls including intensive lot-to-lot
quality controls of 96-well plates coated with primers and
probes as well as precisely pre-defined and technically val-
idated limits of positive controls for quantitative RT-qPCR.
Moreover, quality control was performed for individual
genes-of-interest using a “noise model,” previously con-
structed from an independent large data set of replicate
measurements [14]. The “noise model” estimates the vari-
ance of replicate-to-replicate noise from the Ct value and
identifies and removes outliers within replicates. Outlier
detection and removal in a complex test based on normal-
ized expressions of several genes is crucial since outliers
occur frequently and is possible only if at least three repli-
cates for each gene are measured. Using two replicates only
raises the portion of invalid test outcomes significantly,
leading to a high number of repetitions of the whole EP
test. Using one replicate only does not allow to detect out-
liers resulting in incorrect EP test results. A further reason
for the robust decentral performance of the EndoPredict
assay was the use of a standardized qPCR system as well
as a reproducible technique to isolate RNA from FFPE
tissue, which was extensively evaluated for RNA biomarker
testing in previous studies [16, 18]. Finally, each participant
performed a pre-defined analytical validation of the perfor-
mance characteristics of the EndoPredict assay before pro-
ficiency testing.
The current evaluation needs to be continued to include
other centers and additional samples to control for variation
in molecular pathology laboratory standard operating pro-
cedures in different institutions and regions, and a validation
programme for this is currently in preparation. While in our
study, all 70 samples were assigned to the correct EP risk
group; it should be mentioned that risk group assignment
might vary for those samples with an EP score within 0.5
score units (2 SD) near the cutoff. In this situation, the
estimated risk of distant metastasis, which is reported as a
continuous parameter, might be useful for the interpretation
of results. This study shows that RT-qPCR-based quantita-
tive multigene expression analysis of FFPE tissue samples
including algorithmic analysis is feasible in a decentral
multicenter setting in diagnostic pathology laboratories.
This opens the door for a new generation of molecular
diagnostic tests in breast cancer that might add relevant
information to the standard immunohistochemistry ap-
proach without being confined to globally centralized refer-
ence laboratories.
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